Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Galectin Therapeutics Inc GALT

Healthcare Biotechnology
Galectin Therapeutics, Inc. is a clinical stage biopharmaceutical company dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer. The Company's drug candidates are based on its method of targeting galectin proteins, which are key mediators of biologic and pathologic functions. The Company's lead drug, belapectin, is a carbohydrate-based... see more

Recent & Breaking News (NDAQ:GALT)

Galectin Therapeutics Announces Results from Phase 2b NASH-CX Trial

GlobeNewswire December 5, 2017

Galectin Therapeutics to Present Results from Phase 2b NASH-CX Trial on December 5, 2017

GlobeNewswire December 4, 2017

Galectin Therapeutics CEO Peter G. Traber, M.D. Named Chair of the Anti-Fibrotic Drug Development Summit 2017

GlobeNewswire November 13, 2017

Combination Immunotherapy of Pembrolizumab with the Galectin-3 Inhibitor GR-MD-02 Shows Promising Early Results in Treatment of Advanced Melanoma from a Phase 1b Clinical Trial

GlobeNewswire November 13, 2017

Galectin Therapeutics Reports 2017 Third Quarter Financial Results and Provides Business Update

GlobeNewswire November 7, 2017

Galectin Therapeutics to Present Clinical Data at The Liver Meeting® 2017 Demonstrating the Ability of Non-Invasive Test to Identify Clinically Significant Portal Hypertension in Patients with Compensated NASH Cirrhosis

GlobeNewswire October 20, 2017

Galectin Therapeutics CEO Peter G. Traber, M.D. Named Chair of the Conference for NASH Summit Europe 2017

GlobeNewswire September 25, 2017

Galectin Therapeutics Receives Notice of Chinese Allowance to Grant a Key Patent for Composition of Matter for GR-MD-02

GlobeNewswire September 12, 2017

Galectin Therapeutics to Present at the Rodman & Renshaw 19th Annual Global Investment Conference

GlobeNewswire September 5, 2017

Clarification: Galectin Therapeutics Reports 2017 Second Quarter Financial Results and Provides Business Update

GlobeNewswire August 18, 2017

Galectin Therapeutics Reports 2017 Second Quarter Financial Results and Provides Business Update

GlobeNewswire August 14, 2017

Patent for Enhancing Immunotherapy in Cancer Treatment Granted to Galectin Therapeutics

GlobeNewswire July 25, 2017

Technical Reports on Generic Drugs Equities -- pSivida, Tetraphase Pharma, Catalyst Pharma, and Galectin Therapeutics

PR Newswire July 25, 2017

Galectin Therapeutics to Present at the Singular Research Summer Conference

GlobeNewswire July 7, 2017

Ammo, Inc. Appoints Two Senior Executives to Board of Directors

GlobeNewswire June 29, 2017

Patent for Reducing Inflammatory Response Granted to Galectin Therapeutics

GlobeNewswire June 21, 2017

Galectin Therapeutics Announces Important Milestones towards Completion of NASH CX Trial

GlobeNewswire June 13, 2017

Generic Drugs Stocks on Investors' Radar -- Catalyst Pharma, Lannett, Evoke Pharma, and Galectin Therapeutics

PR Newswire June 7, 2017

Autoimmune Disease Patent Granted to Galectin Therapeutics

GlobeNewswire June 6, 2017

Galectin Therapeutics Reports 2017 First Quarter Financial Results and Provides Business Update

GlobeNewswire May 15, 2017